SUMMARY
# s:**
- Dose-response studies showing therapeutic window without toxicity
- Cell-type specific effects across CNS populations
- Demonstration that enha
## Background and Rationale
# Expanded Experimental Description: Dose-Response and Cell-Type Specific Analysis of Dissolution Enhancement in Neurodegeneration Models
The therapeutic potential of enhancing dissolution pathways in neurodegenerative disease contexts has emerged as a promising intervention strategy, yet the fundamental gap between
METHODOLOGY NOTES
**Phase 1: Cell Line Preparation and Characterization (Days 1-3)**
• Establish primary neuronal cultures from hippocampal, cortical, and dopaminergic regions (n=6 wells per condition)
• Culture CNS cell lines: SH-SY5Y (dopaminergic), HT22 (hippocampal), and primary astrocytes
• Perform cell viability assays (MTT) and characterize baseline stress response markers (HSP70, cleaved caspase-3)
• Validate cell-type specific markers via immunocytochemistry (TH, MAP2, GFAP)
**Phase 2: Compound Preparation and Dose-Response Design (Day 4)**
• Prepare test compound in enhanced dissolution formulation at concentrations: 0.1, 1, 10, 50, 100, 500 μM
• Prepare standard formulation at same concentrations for comparison
• Include vehicle controls (DMSO <0.1%) and positive controls (rotenone 100 nM for toxicity)
**Phase 3: Acute Toxicity Assessment (Days 5-7)**
• Treat cells with dose range for 24h, 48h, and 72h timepoints
• Measure cell viability via MTT assay and LDH release at each timepoint
• Ass